Latest News
Adicet Bio, Inc.
- Adicet Bio, Inc. Estimates – NASDAQ:ACET
- Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
- A new hire waits a year to gain the right to buy Adicet shares
- Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
- An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
- More than half of lupus patients taking Adicet's CAR-T went into remission
- Adicet Bio reports lupus trial results, plans pivotal study
- Adicet Bio (NASDAQ:ACET) Shares Break Above 200-Day Moving Average - Should You Sell?
- Adicet Bio (NASDAQ:ACET) Stock Moved Up to "Hold" by Wall Street Zen
Headlines from the last 30 days, linking to the original publishers. See all market news →